CN1651919A - 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 - Google Patents

结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 Download PDF

Info

Publication number
CN1651919A
CN1651919A CNA2005100079419A CN200510007941A CN1651919A CN 1651919 A CN1651919 A CN 1651919A CN A2005100079419 A CNA2005100079419 A CN A2005100079419A CN 200510007941 A CN200510007941 A CN 200510007941A CN 1651919 A CN1651919 A CN 1651919A
Authority
CN
China
Prior art keywords
cell
insulin
tissue
acceptor
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005100079419A
Other languages
English (en)
Chinese (zh)
Inventor
N·S·凯尼昂
C·瑞科迪
D·W·索马斯
L·布克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
University of Miami
Original Assignee
Biogen Inc
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, University of Miami filed Critical Biogen Inc
Publication of CN1651919A publication Critical patent/CN1651919A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
CNA2005100079419A 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途 Pending CN1651919A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US60/050,267 1997-06-20
US7726598P 1998-03-09 1998-03-09
US60/077,265 1998-03-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB988064413A Division CN1195546C (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Publications (1)

Publication Number Publication Date
CN1651919A true CN1651919A (zh) 2005-08-10

Family

ID=26728084

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100079419A Pending CN1651919A (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途
CNB988064413A Expired - Fee Related CN1195546C (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB988064413A Expired - Fee Related CN1195546C (zh) 1997-06-20 1998-06-19 结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途

Country Status (21)

Country Link
US (2) US20030072754A1 (enExample)
EP (1) EP1051191B1 (enExample)
JP (1) JP2002506446A (enExample)
KR (1) KR100634847B1 (enExample)
CN (2) CN1651919A (enExample)
AT (1) ATE339966T1 (enExample)
AU (1) AU730763B2 (enExample)
BG (1) BG64976B1 (enExample)
BR (1) BR9810620A (enExample)
CA (1) CA2294154A1 (enExample)
DE (1) DE69835965T2 (enExample)
EA (1) EA002550B1 (enExample)
EE (1) EE9900588A (enExample)
HU (1) HUP0003160A3 (enExample)
IL (1) IL133303A0 (enExample)
IS (1) IS5273A (enExample)
NO (1) NO996275L (enExample)
NZ (1) NZ502052A (enExample)
SK (1) SK180299A3 (enExample)
TR (1) TR199903142T2 (enExample)
WO (1) WO1998058669A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949572A (zh) * 2015-06-23 2018-04-20 首尔大学校产学协力团 Cd154结合多肽及其用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2001093908A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
DK1639014T3 (da) * 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
WO2006054305A2 (en) * 2004-11-22 2006-05-26 Ramot At Tel Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
WO2010093467A1 (en) * 2009-02-10 2010-08-19 The Trustees Of Columbia University In The City Of New York Methods for inducing transplantation tolerance
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949572A (zh) * 2015-06-23 2018-04-20 首尔大学校产学协力团 Cd154结合多肽及其用途
CN107949572B (zh) * 2015-06-23 2021-10-26 首尔大学校产学协力团 Cd154结合多肽及其用途

Also Published As

Publication number Publication date
AU7983098A (en) 1999-01-04
NO996275L (no) 2000-02-21
EA002550B1 (ru) 2002-06-27
EA200000058A1 (ru) 2000-08-28
NO996275D0 (no) 1999-12-17
WO1998058669A3 (en) 1999-04-29
KR100634847B1 (ko) 2006-10-17
EP1051191A2 (en) 2000-11-15
CN1195546C (zh) 2005-04-06
BG104091A (en) 2000-10-31
HUP0003160A2 (hu) 2001-01-29
IL133303A0 (en) 2001-04-30
US20030072754A1 (en) 2003-04-17
DE69835965D1 (de) 2006-11-02
TR199903142T2 (xx) 2000-09-21
SK180299A3 (en) 2000-06-12
CN1261286A (zh) 2000-07-26
WO1998058669A2 (en) 1998-12-30
AU730763B2 (en) 2001-03-15
US20070292440A1 (en) 2007-12-20
JP2002506446A (ja) 2002-02-26
HK1033548A1 (en) 2001-09-07
BR9810620A (pt) 2000-10-03
IS5273A (is) 1999-11-26
BG64976B1 (bg) 2006-11-30
DE69835965T2 (de) 2007-06-14
HUP0003160A3 (en) 2002-09-30
NZ502052A (en) 2001-01-26
CA2294154A1 (en) 1998-12-30
KR20010013965A (ko) 2001-02-26
EP1051191B1 (en) 2006-09-20
EE9900588A (et) 2000-08-15
ATE339966T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
CN1261286A (zh) 用于胰岛组织移植的cd154阻断治疗
CN1134266C (zh) 用于组织或器官移植物诱导t细胞耐受的方法
CN1202864C (zh) Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
EP1484063A2 (en) Method for inhibiting rejection of transplanted tissue
US20030170239A1 (en) Immunotherapeutic method to prevent islet cell rejection
EP1009432A1 (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
CN1248921A (zh) 抗cd40l化合物的治疗性施用方法
EP1754490A2 (en) CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
PL191122B1 (pl) Zastosowania przerywacza wiązania CD40:CD154
HK1033548B (en) Cd154 blockade therapy for pancreatic islet tissue transplantation in primates
MXPA99011740A (en) Cd154 blockade therapy for pancreatic islet tissue transplantation
WO1999045958A1 (en) Cd154 blockade therapy for modulation of immune responses to implanted devices
CN1736483A (zh) 应用cd40：cd154结合阻断物预防反适应性免疫应答,特别是移植物排斥反应
CZ461699A3 (cs) Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín
Burkly et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory...

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication